Skye Enterprise Value Over E B I T D A from 2010 to 2024
| SKYE Stock | USD 3.62 0.03 0.82% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (1.65) | Current Value (1.57) | Quarterly Volatility 7.3 K |
Check Skye Bioscience, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Skye Bioscience,'s main balance sheet or income statement drivers, such as Interest Expense of 567.6 K, Income Tax Expense of 2.8 K or Tax Provision of 3 K, as well as many indicators such as Price To Sales Ratio of 275, Dividend Yield of 0.0 or Days Sales Outstanding of 29.72. Skye financial statements analysis is a perfect complement when working with Skye Bioscience, Valuation or Volatility modules.
Skye | Enterprise Value Over E B I T D A |
Latest Skye Bioscience,'s Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Skye Bioscience, Common over the last few years. It is Skye Bioscience,'s Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Skye Bioscience,'s overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Skye Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 1,609 | |
| Geometric Mean | 10.95 | |
| Coefficient Of Variation | 454.03 | |
| Mean Deviation | 4,365 | |
| Median | (1.19) | |
| Standard Deviation | 7,305 | |
| Sample Variance | 53.4M | |
| Range | 29.8K | |
| R-Value | (0.38) | |
| Mean Square Error | 49.1M | |
| R-Squared | 0.15 | |
| Significance | 0.16 | |
| Slope | (623.93) | |
| Total Sum of Squares | 747M |
Skye Enterprise Value Over E B I T D A History
About Skye Bioscience, Financial Statements
Skye Bioscience, stakeholders use historical fundamental indicators, such as Skye Bioscience,'s Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Skye Bioscience, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Skye Bioscience,'s assets and liabilities are reflected in the revenues and expenses on Skye Bioscience,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Skye Bioscience, Common. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (1.65) | (1.57) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out the analysis of Skye Bioscience, Correlation against competitors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.